With the addition of Biogen, CTTV officials hope more compounds entering clinical trials will be deemed safe and effective, which in turn would lead to more medications making it to the market.
“We are committed to advancing evidence-based target discovery and opening up the field for researchers to create innovative methods and tools to accelerate the development of new medicines,” Sally John, vice president of computational biology and genomics at Biogen, said. “Being part of the CTTV helps us realize this vision and provides a practical, harmonized way to share data with the scientific community.”
CTTV recently implemented its Target Validation Platform to help researchers have access to therapeutic targets that could lead to new medicines.
“The importance of accessing and managing searchable, structured data is critical to aring knowledge on target validation,” Philip Ma, Biogen's vice president of digital health technology and data sciences, said.
Jeffrey Barrett, CTTV director, expressed his approval of adding Biogen to the organization.
“The pre-competitive nature of CTTV is critical: the collaboration of our members allows us to make the most of commercial R&D practice while making the data and information available to everyone,” he said.
Biogen Idec is the oldest independent biotechnology company in the world.